Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2526)

VOLUNTARY ANNOUNCEMENT ENTERING INTO A STRATEGIC COOPERATION AGREEMENT WITH YONGJIANG LABORATORY

This announcement is made by Hangzhou Diagens Biotechnology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that recently, the Company entered into a strategic cooperation agreement (the "**Agreement**") with Yongjiang Laboratory (邕江實驗室) (the "**Yongjiang Laboratory**"), a key digital intelligence innovation platform developed by the Guangxi Zhuang Autonomous Region, to jointly promote the training, optimization, validation and demonstration application of large-scale models for medical imaging in Guangxi. The term of cooperation shall be three years commencing from the date on which the Agreement is signed and becomes effective.

Both parties intend to leverage the regional coordination capabilities of Yongjiang Laboratory to align with the clinical diagnosis and treatment and medical insurance application scenarios of healthcare institutions at different levels within Guangxi, and, in conjunction with the Group's iMedImage® foundation model for medical imaging and intelligent hardware and software product capabilities, to carry out model training, deployment optimization, multi-center clinical validation, testing and evaluation, and demonstration application. Furthermore, based on the application outcomes of benchmark demonstration hospitals and regional medical consortia in Guangxi, the parties intend to promote the relevant solutions to healthcare and medical insurance systems nationwide, and leverage Guangxi's geographical advantage as a gateway to Association of Southeast Asian Nations ("**ASEAN**") to explore medical technology cooperation targeting ASEAN and the export of hardware and software products.

The Board considers that the cooperation will enable the Group to leverage Guangxi's multi-tiered healthcare settings to enrich the conditions for model training and clinical validation, enhance its capabilities in scenario adaptation and service deployment, and accelerate the large-scale application and commercialization of the Group's large-scale models for medical imaging. The demonstration application in Guangxi may also serve as a reference for nationwide promotion and, leveraging its geographical advantage as a gateway to ASEAN, create favorable conditions for the Group to expand into overseas markets and promote the export of intelligent healthcare solutions from China. The cooperation is in the interests of the Company and its shareholders as a whole.

About the Group

The Group is a technology company driving innovation in medical diagnosis through artificial intelligence. It has developed iMedImage®, a foundation model that serves as the "core general-purpose brain" for medical imaging, and has built upon it the iMedLoop™ medical imaging AI research and production acceleration platform. This platform combines medical imaging data with doctors' clinical experience, supports experts in developing new models and research tools, and transforms expert experience into replicable and deployable models and products, facilitating medical research and diagnosis and treatment innovation, and improving the efficiency and quality of medical imaging diagnostics.

About the Yongjiang Laboratory

Yongjiang Laboratory is a key digital intelligence innovation platform developed by the Guangxi Zhuang Autonomous Region and oriented towards ASEAN. With trusted data and intelligence as its principal focus, it focuses on research and development as well as application validation in areas including cross-border data circulation and utilization, artificial intelligence, and healthcare. The laboratory is committed to coordinating scientific research institutions, medical institutions and industry resources to advance technological breakthroughs, scenario validation and commercialization of research outcomes, thereby supporting digital intelligence cooperation between Guangxi and ASEAN. To the best of the Directors' knowledge, Yongjiang Laboratory is an independent third party of the Company.

Forward-looking Statement

Statements contained in this announcement regarding the cooperation prospects and expected benefits are forward-looking in nature, and no warranties are given that they will be realized. Any specific cooperation projects and commercial arrangements are subject to the execution of definitive contracts by both parties and the completion of applicable data authorization, ethical review and medical regulatory procedures. This announcement does not constitute any revenue or profit forecast or commitment. The Company will make further announcement(s) in due course in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and applicable laws and regulations.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board, Executive Director and General Manager

Hangzhou, PRC, November 6, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.